Clinical trial NCT00294736: A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
Official title: A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva® (Erlotinib) in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue To Smoke After Failure of One or Two Prior Chemotherapy Regimens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: NSCLC
Keywords: lung cancer
erlotinib
NSCLC
smokers
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2006-02-22
Enrollment: 57
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label, randomized phase 1 study of escalating doses of Tarceva in patients with advanced NSCLC who currently smoke.

Part I will establish the maximum tolerated dose (MTD) of Tarceva in current smokers.

In Part II, patients will be randomized 1:1 to two treatment groups: Arm A (Tarceva MTD established in Part I) and Arm B (150 mg Tarceva daily). Patients in both arms will be treated for two weeks and then have pharmacokinetic samples collected on day 14. Part II is open as of Nov-2006.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of stage IIIB/IV NSCLC;
* Must have received 1 or 2 prior chemotherapy regimens for advanced NSCLC and now have progressive disease;
* Must have recovered from any treatment-related toxicities prior to registration, except for alopecia, grade 1 fatigue, or grade 1 neurotoxicity;
* A current cigarette smoker (minimum of 10 cigarettes per day for \>= 1 year and have a positive test for cotinine) despite advice and support to quit;
* Age \>= 18 years;
* ECOG PS 0-1 and predicted life expectancy \>= 12 weeks;
* Previous surgery is permitted provided that wound healing has occurred prior to registration;
* Adequate hematopoietic, hepatic and renal function defined as follows: ANC \>= 1.5 x 10\^9/L, platelets \>= 100 x 10\^9/L, bilirubin \<= 1.5 x ULN, ALT \<= 2.5 x ULN (or 5 x ULN in case of liver metastases), creatinine \<= 1.5 x ULN;
* No prior treatment with Tarceva or gefitinib (or other drug with significant activity against EGFR (eg, cetuximab and/or ZD6474));
* Patients with reproductive potential must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test within 14 days prior to registration;
* Accessible for repeat dosing and follow-up.

Exclusion Criteria:

* Any concurrent anticancer cytostatic or cytotoxic chemotherapy;
* Concomitant CYP3A4 or CYP1A2 inducers/inhibitors (or during 14 days prior to study) with the exception of tobacco;
* Other active malignancies, unless disease-free and without cancer-specific therapy for at least the last 5 years. Basal or squamous cell skin cancers are not excluded;
* Significant history of cardiac disease unless the disease is well-controlled;
* Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study;
* History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements; of the study or to provide informed consent.
* Gastrointestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption;
* Clinically significant ophthalmologic abnormalities;
* Pregnant or breast-feeding females. Males or females not practicing effective birth control;
* Symptomatic brain metastases which are not stable, require steroids, or that have required radiation within the last 28 days;
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug;

Primary outcomes:
measure: To establish the MTD of Tarceva in currently smoking patients with stage IIIB/IV NSCLC.
timeFrame: 2 years
Secondary outcomes:
measure: To evaluate the survival of currently smoking patients with stage IIIB/IV NSCLC when given Tarceva at the MTD and 150 mg.
timeFrame: 2 years
Other outcomes:
Locations:
city: Bakersfield
country: United States
facility: Comprehensive Blood and Cancer Center
state: California
city: Winston-Salem
country: United States
facility: Wake Forest University Comprehensive Cancer Center
state: North Carolina
city: Edinburgh
country: United Kingdom
facility: University of Edinburgh,Division of Oncology,
state: Scotland
city: Aberdeen
country: United Kingdom
facility: Aberdeen Royal Infirmary
city: Dundee
country: United Kingdom
facility: Ninewells Hospital
city: Glasgow
country: United Kingdom
facility: Beatson West of Scotland Cancer Centre
city: Newcastle upon Tyne
country: United Kingdom
facility: Sir Bobby Robson Cancer Trials Research Centre
city: Sheffield
country: United Kingdom
facility: Department of Oncology
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital
Study officials:
affiliation: OSI Pharmaceuticals
name: Medical Monitor
role: STUDY_DIRECTOR
References: